AbbVie completes acquisition of Cerevel Therapeutics
Michael Vi/iStock Editorial by way of Getty Photos AbbVie (NYSE:ABBV) has accomplished its ~$8.7B ($45 per share) acquisition of Cerevel ...
Friday, November 8, 2024
Tag: AbbVie
AbbVie Broadcasts European Fee Approval of SKYRIZI ® (risankizumab) for the Remedy of Adults with Reasonably to Severely Energetic Ulcerative Colitis
The advertising authorization for SKYRIZI ® (risankizumab) marks its fourth accredited indication within the European UnionThe approval is supported by ...
Dividend Kings In Focus: AbbVie
Updated on September 29th, 2023 by Bob Ciura We believe long-term investors should focus on the highest-quality dividend growth stocks. ...
The AbbVie Update: Q1 Spotlight On Life After Humira (NYSE:ABBV)
hamzaturkkol 2023 will be a big year for AbbVie. The company's transition from a Humira-dependent enterprise to one with multiple ...
Dividend Aristocrats In Focus: AbbVie
Updated on February 1st, 2023 by Jonathan Weber At Sure Dividend, we believe long-term investors should focus on the highest-quality ...
AbbVie, Vertex, Genmab among accurate biotech picks at SA for 2022 (NYSE:ABBV)
Panuwat Dangsungnoen/iStock via Getty Images Seeking Contributors urged investors to buy AbbVie (NYSE:ABBV), Vertex Pharma (NASDAQ:VRTX), Genmab (GMAB) and a ...
AbbVie Stock: Get Ready For Humira 2.0 (NYSE:ABBV)
Hailshadow AbbVie (NYSE:ABBV), a $250 billion cap research-based global biopharmaceutical company, will soon be announcing new data from a Phase ...
AbbVie, Roche, Regeneron may considerably profit as AMD market anticipated to soar
Marcelo Ricardo Daros AbbVie (NYSE:ABBV), Roche (OTCQX:RHHBY), and Regeneron Prescription drugs (NASDAQ:REGN), which market and/or are creating new age-related macular ...
RECOMMENDED
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.